Me-Linh Luong1, Mona Al-Dabbagh2, Andreas H Groll3, Zdenek Racil4, Yasuhito Nannya5, Dimitra Mitsani6, Shahid Husain7. 1. Department of Infectious Diseases and Medical Microbiology, Centre Universitaire de l'Université de Montréal (CHUM), University of Montréal, Montréal, Quebec, Canada me-linh.luong.chum@ssss.gouv.qc.ca. 2. Division of Infectious Diseases, Department of Medicine, University of Toronto, University Health Network, Toronto, Ontario, Canada Department of Pediatric, Division of Infectious Diseases, King AbdulAziz Medical City, King Saud bin Abdulaziz University for Health Sciences, Jeddah. Saudi Arabia. 3. Infectious Disease Research Program, Centre for Bone Marrow Transplantation and Department of Pediatric Haematology/Oncology, University Children's Hospital Münster, Münster, Federal Republic of Germany. 4. Department of Internal Medicine-Haematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic. 5. Department of Haematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan. 6. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 7. Division of Infectious Diseases, Department of Medicine, University of Toronto, University Health Network, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Voriconazole therapeutic drug monitoring (TDM) is increasingly used in clinical practice. However, the utility of voriconazole TDM to guide therapy remains uncertain and controversial. We conducted a meta-analysis of studies assessing the relationship between voriconazole serum concentration and clinical outcomes of success and toxicity. METHODS: We searched bibliographic databases for studies on voriconazole serum concentrations and clinical outcomes. We compared success outcomes between patients with therapeutic and subtherapeutic voriconazole serum concentrations, and toxicity outcomes between patients with and without supratherapeutic serum concentrations. RESULTS: Twenty-four studies were analysed. Pooled analysis for efficacy endpoint demonstrated that patients with therapeutic voriconazole serum concentrations (1.0-2.2 mg/L) were more likely to have successful outcomes compared with those with subtherapeutic voriconazole serum concentrations (OR 2.30; 95% CI 1.39-3.81). A therapeutic threshold of 1.0 mg/L was most predictive of successful outcome (OR 1.94; 95% CI 1.04-3.62). Patients with therapeutic concentrations did not have better survival rates. Pooled analysis for toxicity endpoint demonstrated that patients with supratherapeutic voriconazole serum concentrations (4.0-6.0 mg/L) were at increased risk of toxicity (OR 4.17; 95% CI 2.08-8.36). A supratherapeutic threshold of 6.0 mg/L was most predictive of toxicity (OR 4.60; 95% CI 1.49-14.16). CONCLUSIONS: Patients with therapeutic voriconazole serum concentrations were twice as likely to achieve successful outcomes. The likelihood of toxicity associated with supratherapeutic voriconazole serum concentrations was 4-fold that of therapeutic concentrations. Our findings suggest that the use of voriconazole TDM to aim for serum concentrations between 1.0 and 6.0 mg/L during therapy may be warranted to optimize clinical success and minimize toxicity.
BACKGROUND:Voriconazole therapeutic drug monitoring (TDM) is increasingly used in clinical practice. However, the utility of voriconazole TDM to guide therapy remains uncertain and controversial. We conducted a meta-analysis of studies assessing the relationship between voriconazole serum concentration and clinical outcomes of success and toxicity. METHODS: We searched bibliographic databases for studies on voriconazole serum concentrations and clinical outcomes. We compared success outcomes between patients with therapeutic and subtherapeutic voriconazole serum concentrations, and toxicity outcomes between patients with and without supratherapeutic serum concentrations. RESULTS: Twenty-four studies were analysed. Pooled analysis for efficacy endpoint demonstrated that patients with therapeutic voriconazole serum concentrations (1.0-2.2 mg/L) were more likely to have successful outcomes compared with those with subtherapeutic voriconazole serum concentrations (OR 2.30; 95% CI 1.39-3.81). A therapeutic threshold of 1.0 mg/L was most predictive of successful outcome (OR 1.94; 95% CI 1.04-3.62). Patients with therapeutic concentrations did not have better survival rates. Pooled analysis for toxicity endpoint demonstrated that patients with supratherapeutic voriconazole serum concentrations (4.0-6.0 mg/L) were at increased risk of toxicity (OR 4.17; 95% CI 2.08-8.36). A supratherapeutic threshold of 6.0 mg/L was most predictive of toxicity (OR 4.60; 95% CI 1.49-14.16). CONCLUSIONS:Patients with therapeutic voriconazole serum concentrations were twice as likely to achieve successful outcomes. The likelihood of toxicity associated with supratherapeutic voriconazole serum concentrations was 4-fold that of therapeutic concentrations. Our findings suggest that the use of voriconazole TDM to aim for serum concentrations between 1.0 and 6.0 mg/L during therapy may be warranted to optimize clinical success and minimize toxicity.
Authors: I Gueta; R Loebstein; N Markovits; Y Kamari; H Halkin; G Livni; H Yarden-Bilavsky Journal: Eur J Clin Pharmacol Date: 2017-06-17 Impact factor: 2.953
Authors: Andreas H Groll; Georg Hempel; Silke Gastine; Thomas Lehrnbecher; Carsten Müller; Fedja Farowski; Peter Bader; Judith Ullmann-Moskovits; Oliver A Cornely Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Palash Samanta; Cornelius J Clancy; Rachel V Marini; Ryan M Rivosecchi; Erin K McCreary; Ryan K Shields; Bonnie A Falcione; Alex Viehman; Lauren Sacha; Eun Jeong Kwak; Fernanda P Silveira; Pablo G Sanchez; Matthew Morrell; Lloyd Clarke; M Hong Nguyen Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 9.079